ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
A Dual GSH/ROS-Functional NIR Fluorescent Platform for Synergistic Photodynamic Therapy and Radiosensitization in Nasopharyngeal Carcinoma.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
High-precision tumor theranostic systems capable of real time monitoring are imperatively required for optimizing the spatial targeting accuracy during radiotherapy and surgical resection across clinical management of nasopharyngeal carcinoma (NPC). However, the clinical application of photodynamic therapy (PDT) is impeded by the suboptimal reactive oxygen species (ROS) generation efficiency and inadequate visualization of redox procedure. In this study, we developed a theranostic platform HSF, featuring integrated tumor-specific near-infrared (NIR) fluorescence imaging and photodynamic ROS generation for real time monitoring and targeted radiotherapy of solid malignancies for NPC. Mechanistically, HSF was initially activated by the elevated glutathione (GSH) levels in the tumor microenvironment, which concomitantly turned on its NIR fluorescence and photodynamic properties. The resulting NIR fluorescence allowed for tumor visualization, while the PDT-triggered oxidative stress further consumed intracellular GSH, thereby ultimately inducing ferroptosis. In NPC cell-derived xenograft models, HSF demonstrated exceptional biocompatibility and effective in vivo retention. This multifunctional photosensitizer enabled precise radiotherapy navigation via real time fluorescent monitoring and ferroptosis-mediated therapeutic mechanisms, offering a transformative approach for real time visualization-guided NPC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.